Please visit our MS learning channel on Youtube, which provides hundreds of topics from our education programs, that were video-recorded and archived here: www.youtube.com/msviewsandnews

joomla ecommerce template -- Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

=================

CHAMPIONS TACKLING MS - AWARDS Dinner, Honoring Aaron Boster, MD and Jon e. Glaser, DDS - now open for registration. Visit www.events.msvn.org

Saturday, November 28, 2015

The Basics of MS Treatments now as opposed to 20 years ago - Video Interview with Brian Steingo, MD



Video recorded - November 2015

a 17minute:38second (17:38) video recorded interview on
MS Medications, MRI, MS Relapse and Vitamin D




~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
MS Views and News helps to provide information for all affected by MS
Keep up to date with the news and information we provide 
by signing up by clicking here
.===================================

2015 MS Symposium - The Neurological Aspects of MS -




Program date 11.14.15


~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
MS Views and News helps to provide information for all affected by MS
Keep up to date with the news and information we provide 
by signing up by clicking here
.===================================

Another Study Focused on Stem Cells and Autoimmune Diseases Shows Promise

Another Study Focused on Stem Cells and Autoimmune Diseases Shows Promise

Researchers at Monash University and the MIMR-PHI Institute of Medical Research in Australia recently proposed that specific human stem cells with immunomodulatory properties represent a new promising therapeutic strategy for diseases like multiple sclerosis (MS). The study was published in the Journal of Neuroinflammation and is entitled “Immunosuppressive potential of human amnion epithelial cells in the treatment of experimental autoimmune encephalomyelitis.
MS is a progressive neurodegenerative autoimmune disorder that results from an attack on the central nervous system by the body’s own immune system (through auto-reactive T cells), causing inflammation and damage to the myelin layer that covers and protects nerve fibers. Myelin loss leads to impairment in signal transmission along the nerve fibers, affecting motor function (coordination, balance, speech and vision), causing irreversible neurological disability and paralysis. It is estimated that more than 2.3 million people in the world suffer from the disease.
Recent research has shown that stem cells (cells with the potential to differentiate into several specialized cell types) like human amnion epithelial cells (hAECs), isolated from the amniotic membrane that covers the fetus, have the ability to modulate immune responses both in vitro and in vivo and to differentiate into clinically relevant cell types.
In the study, researchers analyzed the immunoregulatory properties of hAECs as a potential therapy for an MS-like disorder known as experimental autoimmune encephalomyelitis (EAE) in mice. The team assessed the immunomodulatory properties of hAECs in vitro and tested its therapeutic efficacy in EAE mice models. T cell response and phenotype were also determined.
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Keep up to date with the news and information we provide 
by signing up by clicking here
.===================================

Opexa Therapeutics’ MS Therapy Selected as ‘Top Project to Watch’


<span class="entry-title">Opexa Therapeutics’ MS Therapy Selected as ‘Top Project to Watch’</span><span class="entry-subtitle">Company's work in personalized immunotherapies honored for 3rd consecutive year</span>

Company's work in personalized immunotherapies honored for 3rd consecutive year

Opexa Therapeutics, Inc., announced that it has been named one of the “Top Projects to Watch” for the third consecutive year. A panel of independent experts recognized the biopharmaceutical company for its work in the development of personalized immunotherapies for autoimmune disorders, such as multiple sclerosis (MS) and neuromyelitis optica (NMO).
Opexa was among eight companies whose efforts in six therapeutic areas were selected as top projects, out of hundreds of compounds considered by the panel for their potential as products. The selection was announced at the recent Therapeutic Area Partnerships meeting in Boston, where Opexa’s President and CEO Neil K. Warma presented an overview of his company.
“Selected companies…  represent what our committees consider among the most attractive opportunities the industry has to offer,” Marc Wortman, Editorial Director at Therapeutic Area Partnerships, said in a press release. “Winners have met rigorous criteria, including: unmet medical need, market potential, diversity of indications, strong science, multi-level partnering opportunities (biotech and pharma), potential for new opportunities beyond initial indications and corporate stability. As the industry leader in strategic analysis and transaction tracking, our main goal is to give these companies exposure to potential investors, partners, and acquirers.”
read more


~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

Keep up to date with the news and information we provide 
by signing up by clicking here
.===================================

Friday, November 27, 2015

Takeda introduces multiple sclerosis drug Copaxone subcutaneous injection 20 mg syringe in Japan

Osaka, Japan
Friday, November 27, 2015, 12:00 Hrs  [IST]
Takeda Pharmaceutical Company Limited, a research-based global company, announced that the multiple sclerosis treatment drug, 'Copaxone subcutaneous injection 20 mg syringe' (glatiramer acetate) has become available in Japan.

This drug has been developed by Teva Pharmaceutical Industries Ltd. as a subcutaneous injection administered once daily, to prevent the relapse of multiple sclerosis. Copaxone was designated as an orphan drug by the Japanese Ministry of Health, Labour and Welfare (MHLW) in March 2009, and a request was received from the MHLW in May 2010 for its development as an "unapproved drug highly needed in medical care". In March 2013, Takeda and Teva entered into a licensing agreement for commercialisation of this drug in Japan, and on September 28, 2015 Takeda obtained NDA approval. It was listed in the NHI (National Health Insurance) Price List today.

Multiple sclerosis is assumed to be an autoimmune disease, the hallmark sign of which is inflammatory demyelination of the central nervous system characterized by demyelinating plaques in the brain and the spinal cord. Common symptoms of multiple sclerosis include visual problems, ocular motor abnormality, paresthesia, muscle weakness, spasticity, urinary dysfunction, and cognitive impairment. This disease may present as a primary progressive type, which takes a chronic progressive course from its early onset; a relapsing-remitting type, which repeats a pattern of relapse and remission; or a secondary progressive type that shifts to a progressive course later. More than 80 per cent of patients are categorized as having the relapsing-remitting type. Multiple sclerosis is estimated to affect approximately 18,000 individuals in Japan, with its prevalence tending to increase.



~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
MS Views and News helps to provide information for all affected by MS
Keep up to date with the news and information we provide 
by signing up by clicking here
.===================================

Sunday, November 22, 2015

Brief Cognitive Assessment Tool in MS Good for Everyday Use

The Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) is a effective tool in everyday clinical practice for the identification of cognitive impairment (CI) in patients with MS, an Italian study has confirmed.


The study also highlighted the good psychometric properties of the symbol digit modalities test (SDMT), Maria P. Amato, MD, of the University of Florence, Italy, 
and colleagues reported online in BMC Neurology.


"It seems important to stress that, in optimal clinical conditions, where a neuropsychologist can take care of the cognitive assessment, it is preferable to 
achieve a more thorough cognitive evaluation using tools including 
neuropsychological tests that investigate several cognitive domains impaired in MS," said the investigators. "The implementation of BICAMS is still in its infancy," they noted.


The study showed that when BICAMS was compared with other commonly used neuropsychological batteries used in MS, such as the Brief Repeatable Battery (BRB), neither BICAMS nor BRB were equivalent to SDMT in the assessment of CI in MS. This is in keeping with the recent literature, pointed out the investigators.


"On the basis of our results, the agreement between the BICAMS and the BRB is fair 
to moderate and mainly dependent on the inclusion of the SDMT, which is the only common test between the two batteries," they reported. "We can hypothesize that 
the BICAMS and the BRB cannot be considered as equivalent in the assessment of CI
in MS."

.===================================

CME event "RISKY BUSINESS": Understanding and Attenuating Risk Associated with Disease-Modifying Therapy in Relapsing-Remitting Multiple Sclerosis

Multiple sclerosis (MS) strikes people in the prime of their lives, affecting upwards of 400,000 people in the United States and 2.5 million worldwide. However, a diagnosis of MS is no longer a sentence of doom; “the MS landscape has been comprehensively and irreversibly transformed by progress” in understanding the pathophysiology of the disease and the development of targeted therapy. 

As new therapeutic options become available, establishing effective patient-centric treatment plans, based upon newly identified targets and incorporating mechanism of action, will be increasingly essential to achieving optimum quality of life for all of these individuals.

In this neuroscience CME Live and On Demand faculty will share the evidence and their insights with health care providers to enable them to collaboratively engage patients in a discussion about their disease and develop shared treatment goals to improve outcomes in patients with MS.
Healthcare Providers: Click here to learn more of this event




~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Keep up to date with the news and information we provide by signing up by clicking here
.===================================